Wire · opportunities
Why the best drug candidates get missed by narrow screens
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
Proxygen's innovative screening method for molecular glue degraders starts from the outcome—disease protein elimination—rather than a defined mechanism, allowing discovery of drug candidates missed by traditional target-E3 ligase focused approaches. Their approach targets difficult proteins without conventional binding pockets and optimizes hits through multidimensional profiling, advancing lead programs toward clinical trials.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
You can avoid missing top drug candidates by reversing the screening process: focus on the disease protein’s removal first, then find how it happens. Drug developers targeting hard-to-drug proteins must explore beyond traditional binding sites to capture breakthrough therapies.
◆ Coverage
1 source · 10 Sep 2026
◆ Related on Wire
◆ Topics